Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Antiangiogenic VEGF isoform in inflammatory myopathies.
[inclusion body myositis]
To
investigate
expression
of
vascular
endothelial
growth
factor
(
VEGF
)
antiangiogenic
isoform
A-
165
b
on
human
muscle
in
idiopathic
inflammatory
myopathies
(
IIM
)
and
to
compare
distribution
of
angiogenic
/
antiangiogenic
VEGFs
,
as
isoforms
shifts
are
described
in
other
autoimmune
disorders
.
We
analyzed
VEGF-A
165
b
and
VEGF-A
by
western
blot
and
immunohistochemistry
on
skeletal
muscle
biopsies
from
21
patients
affected
with
IIM
(
polymyositis
,
dermatomyositis
,
and
inclusion
body
myositis
)
and
6
control
muscle
samples
.
TGF-
β
,
a
prominent
VEGF
inductor
,
was
analogously
evaluated
.
Intergroup
differences
of
western
blot
bands
density
were
statistically
examined
.
Endomysial
vascularization
,
inflammatory
score
,
and
muscle
regeneration
,
as
pathological
parameters
of
IIM
,
were
quantitatively
determined
and
their
levels
were
confronted
with
VEGF
expression
.
V
EGF-A
165
b
was
significantly
upregulated
in
IIM
,
as
well
as
TGF-
β
.
VEGF-A
was
diffusely
expressed
on
unaffected
myofibers
,
whereas
regenerating
/
atrophic
myofibres
strongly
reacted
for
both
VEGF-A
isoforms
.
Most
inflammatory
cells
and
endomysial
vessels
expressed
both
isoforms
.
VEGF-A
165
b
levels
were
in
positive
correlation
to
inflammatory
score
,
endomysial
vascularization
,
and
TGF-
β
.
Our
findings
indicate
skeletal
muscle
expression
of
antiangiogenic
VEGF-A
165
b
and
preferential
upregulation
in
IIM
,
suggesting
that
modulation
of
VEGF-A
isoforms
may
occur
in
myositides
.
Diseases
Validation
Diseases presenting
"endomysial vascularization"
symptom
inclusion body myositis
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom